Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
Authors' conclusion
In participants with T2D, regardless of baseline BMI, treatment with tirzepatide resulted in statistically significant and clinically meaningful glycaemic reductions and body weight reductions compared with insulin glargine, with a safety profile consistent with previous reports.
Study context
- Population
- Participants with T2D from the SURPASS-AP-Combo trial, categorised into body mass index (BMI) subgroups: normal weight (<25 kg/m²), overweight (≥25 and <30 kg/m²), obese (≥30 kg/m²); BMI <25 kg/m² 235 (25.9%), ≥25 to <30 kg/m² 458 (50.5%), ≥30 kg/m² 214 (23.6%)3 BMI subgroups
- Participants
- 907 participants
- Comparison
- Tirzepatide vs insulin glargine, by baseline BMI
Methodological detailsexploratory subgroup analysis, phase 3
- Exploratory subgroup analysis
- Phase 3
Primary result
As reported in the abstract
Change in mean HbA1c across BMI subgroups · Week 40
Tirzepatide
−2.0% to −2.8%
mean
Insulin glargine
−0.8% to −1.0%
mean
Further findings
| Outcome | Tirzepatide | Insulin glargine |
|---|---|---|
| Percent change in body weight across BMI subgroups · Week 40 | −5.5% to −10.8% | 1.0% to 2.5% |
Percent change in body weight across BMI subgroups · Week 40
- Greater percent change in body weight with all tirzepatide doses vs insulin glargine across the BMI subgroups
Treatment goals for HbA1c and body weight reduction
- Higher proportion of tirzepatide-treated participants achieved treatment goals vs insulin glargine
Other cardiometabolic indicators
- Improvements observed with tirzepatide across all BMI subgroups
Safety
- Safety profile of tirzepatide similar across all BMI subgroups
- Most frequent AEs with tirzepatide: gastrointestinal-related events and decreased appetite, with relatively few leading to treatment discontinuation
Original publication
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo. Diabetes Obes Metab. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →